Assignment

Diagnosis, Molecular Pathogenesis, and Treatment of Cervical Cancer in Pregnant Women

Student Name
Institution
Course
Professor
Date

Abstract

Cervical cancer is a significant health concern in women worldwide, and its diagnosis, molecular pathogenesis, and treatment pose unique challenges when it occurs during pregnancy. This essay covers the epidemiology, molecular pathogenesis, clinical signs, screening and diagnostic tools, therapy choices, and current clinical care recommendations for cervical cancer in pregnant women. Although cervical cancer during pregnancy is rare, affecting 1 in 1,000 pregnancies, delayed detection, and restricted treatment choices, especially in low-resource settings, can have a major impact. Persistent high-risk human papillomavirus (HPV) infection causes cell cycle dysregulation and tumor suppressor gene inactivation. Clinical signs, including abnormal vaginal bleeding, can be ignored or attributed to pregnancy-related changes, requiring careful assessment. VIA and Pap smears are safe screening procedures, while colposcopy with biopsy confirms the diagnosis. Conservative treatments include surveillance, fertility-preserving procedures, and cerclage for cervical incompetence. Considering gestational age and cancer stage, a multidisciplinary team provides individualized care to maximize mother and fetus outcomes.

Diagnosis, Molecular Pathogenesis, and Treatment of Cervical Cancer in Pregnant Women

Introduction

A major global health issue is cervical cancer, which is caused by persistent infection with high-risk HPV strains like HPV16 and HPV18. Cervical epithelial cells undergo molecular changes that cause cervical cancer. After HPV infection, viral DNA integrates into the host genome, disrupting cellular processes (Canepa et al., 2019). E6 and E7 viral oncoproteins degrade tumor suppressor proteins p53 and pRb, respectively, facilitating this integration event. Thus, cell cycle regulatory mechanisms are dysregulated, causing uncontrolled cell proliferation and genetic abnormalities. Genomic instability accelerates cervical intraepithelial neoplasia (CIN) to aggressive cancer. Molecular changes cause viral antigens like E6 and E7 oncoproteins to be expressed, making them important diagnostic and therapeutic targets. These antigens have revolutionized screening and diagnostic methods, allowing sensitive and specific HPV and early cervical lesion tests. Recognition of viral antigens has also enabled targeted therapeutics like therapeutic vaccinations and immunotherapies to induce an immune response against HPV-associated lesions (Nahand et al., 2019). Despite these advances, screening programs, especially in low-resource areas, and advanced cervical cancer therapies remain difficult. To overcome these obstacles and fight cervical cancer globally, research and comprehensive tactics are needed.

Epidemiology

Cervical cancer affects women of all ages worldwide and causes significant morbidity and mortality. The WHO ranks it the fourth most frequent cancer in women worldwide. Cervical cancer cases and fatalities worldwide were 604,127 and 342,069 in 2020 (Johnson et al., 2019). Low- and middle-income nations account for 85% of cervical cancer cases and 87% of fatalities. In low-resource environments, cervical cancer incidence and mortality are higher for several reasons. Lack of healthcare facilities, screening programs, and awareness of cervical cancer and its risk factors delay diagnosis and treatment. Additionally, socioeconomic gaps, cultural attitudes, and healthcare utilization barriers increase cervical cancer rates in these regions.

The geographical distribution of cervical cancer cases varies. At 25% of global cervical cancer cases, Sub-Saharan Africa has the highest incidence and mortality. The high prevalence of high-risk HPV infections, insufficient screening and treatment, and inadequate healthcare infrastructure contribute to this (Perrone et al., 2019). Due to widespread screening programs like Pap smears and HPV testing and effective treatment options, cervical cancer incidence and mortality have decreased in high-income nations. While cervical cancer mostly affects middle-aged to older women, it can also affect younger women. Incidence rates peak in women aged 35–44 and after that fall. Cervical cancer can afflict women of all ages, especially reproductive-age women (Otto, 2023). Cervical cancer is rare during pregnancy. However, cervical cancer during pregnancy presents particular complications. Increased blood flow to the cervix and hormonal changes during pregnancy can alter cervical cancer growth and clinical appearance. This can delay diagnosis because pregnancy-related changes can cause abnormal vaginal bleeding.

Treatment decisions are complicated by a growing fetus. Obstetricians, gynecologic oncologists, and other healthcare specialists must work together to manage cancer while protecting fetal health.

Molecular Pathogenesis

The molecular pathogenesis of cervical cancer during pregnancy is comparable to that in non-pregnant women. Persistent infection with high-risk HPV types causes chronic cervical epithelial cell infection. Tumor suppressor and cell cycle control genes are disrupted by viral DNA incorporation into the host genome (Martínez-Rodríguez et al., 2021). Cell growth and division are dysregulated, causing uncontrolled proliferation, cervical dysplasia, and invasive carcinoma. Multiple molecular events cause cervical cancer to progress during pregnancy. HPV DNA in the host genome affects the E2 gene, which regulates viral gene expression and replication. The E6 and E7 viral oncogenes, which inhibit p53 and pRb, rise due to this disturbance. Uncontrolled cell proliferation and genomic instability caused by p53 and pRb inactivation accelerate dysplasia to aggressive cancer. Pregnancy hormones also affect HPV-related gene expression and immunological response. Estrogen and progesterone receptors in cervical cancer cells affect tumor growth and invasion (Zhang, 2019). Pregnancy alters the immunological response, which controls HPV infection and tumor growth. These hormonal and immunological alterations produce a unique milieu that can affect cervical cancer molecular etiology in pregnant women.

Clinical Manifestations

Cervical cancer symptoms during pregnancy are comparable to those in non-pregnant women, but they might be missed or attributed to normal physiological changes, delaying detection and treatment. Abnormal vaginal bleeding, including postcoital bleeding, intermenstrual hemorrhage, and excessive, extended monthly bleeding, is the most common symptom of cervical cancer (Pang et al., 2020). However, these symptoms may be misdiagnosed as hormonal or cervical changes during pregnancy, delaying medical intervention. Pregnant cervical cancer patients may have increased vaginal discharge and irregular bleeding. This discharge may be watery, bloody, or foul-smelling. Pregnant women should report any changes in vaginal discharge color, consistency, or odor to their doctors. Although uncommon, cervical cancer can cause pelvic pain. Pelvic pain may radiate to the lower back or thighs. The physiological changes in the cervix during pregnancy can cause bleeding and discharge, making it difficult to distinguish between typical pregnancy changes and cervical cancer indications. Known as cervical ectopy, increased cervix vascularity can cause bleeding or spotting (Hossain et al., 2022). Cervical ectopy occurs when glandular cells surrounding the cervical canal stretch onto the ectocervix, making it more bleedable. Healthcare personnel must keep a high index of suspicion and thoroughly analyze any atypical symptoms reported by pregnant women.

To diagnose cervical cancer in pregnant women, doctors will examine them thoroughly. A thorough medical history should include any abnormal Pap smear results, HPV infection, or cervical abnormalities. Physical examinations may involve pelvic exams to check for cervical lesions or nodules (Dimova et al., 2020). The growing fetus and physiological changes in the cervix make physical inspection difficult during

pregnancy. A colposcopy, which magnifies the cervix, may be used to diagnose cervical cancer. Colposcopy allows doctors to see abnormalities and take tissue samples for investigation. Performing a biopsy during pregnancy needs careful evaluation of the dangers to the fetus and is usually reserved for cases of high cervical cancer suspicion. Early detection and treatment of cervical cancer during pregnancy enhance outcomes for the mother and fetus (Olusola et al., 2019). If cervical cancer is found during pregnancy, obstetricians, gynecologic oncologists, and other specialists will create a personalized treatment strategy. Treatment depends on the cancer stage, pregnancy gestational age, and mother's health. The idea is to balance cancer treatment with fetal well-being.

Screening and Diagnosis

Screening for cervical cancer during pregnancy should occur before conception or early on. Visual inspection with acetic acid (VIA) or Pap smear can safely screen without screening. VIA employs dilute acetic acid to render aberrant cervix regions white, indicating dysplastic or malignant alterations (Esfandyari et al., 2021). However, a Pap smear collects cervix cells for microscopic analysis. Pregnancy screenings can be done safely to protect the mother and fetus. If screening finds an anomaly or a pregnant woman has questionable symptoms, additional evaluation is needed. For more comprehensive aberrant findings, colposcopy with or without biopsy is advised. A specialized microscope examines the cervix, vagina, and vulva during colposcopy. Biopsies from suspect locations can be histopathologically examined to confirm cervical cancer. Colposcopy and biopsy can be done safely during pregnancy with care to protect the fetus. Invasive cancer may require further imaging to assess its severity.

MRI is often used to identify cervical cancer's local spread and probable involvement of neighboring structures like the bladder or rectum. Chest X-rays and CT scans can reveal distant metastases in pregnant cervical cancer patients. These diagnostic techniques help stage cancer and determine its spread beyond the cervix (Hampe et al., 2020). With these imaging examinations and extensive clinical evaluation, healthcare providers may make informed treatment decisions and give patients accurate prognoses. Identifying distant metastases helps choose treatment choices, including systemic medicines like chemotherapy. It also helps healthcare providers analyze the possible effects of metastatic cancer on maternal health and the growing fetus, enabling them to provide comprehensive and individualized treatment throughout management.

Treatment Options

Obstetricians, gynecologic oncologists, and neonatologists must work together to treat cervical cancer in pregnant women for the greatest results. Treatment depends on gestational age, cancer stage, and the woman's desire to continue (Reed et al., 2021). Depending on the mother's oncological demands and the fetus' obstetric needs, there are several therapy choices. Conservative therapy with thorough supervision may be appropriate for early-stage, low-grade lesions, especially in women seeking conception. This method involves clinical exams, imaging investigations, and repeat biopsies to track tumor growth. It delays decisive therapy until after birth, minimizing fetal risks while managing cancer. In

cases of cervical incompetence and preterm labor, cerclage may be performed. To stabilize the cervix and prevent cervical dilatation, cerclage sutures are placed around it. The surgery is usually done in the second trimester, approximately 12–14 weeks, when the cervix is more suitable (Hamilton et al., 2021). The cerclage stitches strengthen the fragile cervix and prevent it from opening early, which could cause preterm labor and difficulties for the mother and fetus. If necessary, cervical cerclage can be safely paired with conization or trachelectomy. Trachelectomy removes the whole cervix while keeping the uterus, while conization removes a cone-shaped section with malignant tissue. The patient's cervical cancer stage and fertility goals determine whether to combine cerclage with these procedures. The combined strategy optimizes outcomes for the mother and fetus by managing cancer and preventing preterm delivery.

Conization or trachelectomy may be considered for advanced cervical cancer. A cone-shaped portion of the cervix with malignant tissue is removed during conization. The uterus is preserved after tracheectomy, which removes the whole cervix (Nayar et al., 2020). These techniques try to eradicate or control cancer while sustaining pregnancy. To check cancer spread, pelvic lymph nodes may be excised in both cases. The oncology and obstetrics teams must plan and coordinate these surgical operations to provide optimal results for the mother and fetus. Due to fetal damage, chemotherapy and radiation are avoided during pregnancy. In advanced cervical cancer instances that threaten the mother's life, individualized treatment approaches may include chemotherapy during pregnancy. The gestational age, chemotherapy medications and their hazards, and the mother's prognosis must be considered before using chemotherapy (Saiki et al., 2020). Fetal development and premature birth will be assessed. Radiation therapy is usually deferred until after delivery to reduce fetal risk (Evans et al., 2023). Postpartum radiation therapy may be needed to treat cancer. For best cancer control, surgery and radiation therapy may be needed. The woman's health, cancer stage, and risk-benefit assessment will determine the treatment method. Pregnant cervical cancer patients need psychosocial assistance and counseling. Cancer during pregnancy can have a tremendous emotional and psychological impact; thus, healthcare practitioners should give adequate support and tools to address these unique problems.

Current Clinical Management Recommendations

Current clinical management guidelines for cervical cancer in pregnant women stress customized care based on a thorough patient assessment. The right cervical cancer treatment depends on its stage. Microinvasive or stage IA1 malignancies may be managed conservatively with close surveillance (Almonte et al., 2020). These patients get regular cervical exams, including colposcopy and biopsies, to track disease progression. MRI and ultrasonography can also assess tumor size and invasion. Treatment decisions depend on gestational age. First-trimester women with early-stage illness can wait for therapy until after birth without harming maternal outcomes. However, women in the second or third trimester may need to adjust their therapy to balance cancer control with fetal well-being. Gynecologic oncologists, obstetricians, and neonatologists will collaborate on a personalized treatment strategy in such circumstances.

Throughout treatment, the disease and fetus must be monitored. Regular cervical exams assess tumor size, location, and therapy response. Imaging investigations like MRI or ultrasonography may reveal tumor features and lymph node involvement. Ultrasounds are also essential to monitor fetal growth, well-being, and amniotic fluid levels. Oncologists and obstetricians must work together to improve maternal and fetal outcomes (Radaic et al., 2021). The treatment approach should be carefully planned to provide the greatest care for the mother and fetus. Multiple disciplines meet regularly to assess patient progress, consider treatment alternatives, and make adjustments as needed. If advanced sickness or maternal health issues require abortion, the lady and her family should get counseling and support. This includes fertility concerns, emotional assistance, and resource recommendations. Beyond medical care, comprehensive care includes the patient's psychosocial and emotional well-being and support system.

In conclusion, treating cervical cancer during pregnancy demands a thorough and tailored approach that meets its particular problems. Early detection and management require timely screening and precise diagnosis. Treatment selections depend on the cancer stage, gestational age, and the woman's pregnancy wishes. Obstetricians, gynecologic oncologists, and neonatologists must work together to improve maternal and fetal outcomes. The molecular pathogenesis of cervical cancer has become better understood, but more study is needed to create safe and effective treatments for pregnant women. By improving our understanding and methods, we can give pregnant women with cervical cancer the greatest care, protecting both the mother and the fetus. In addition to earlier screening and proper diagnosis, cervical cancer management during pregnancy requires careful assessment of treatment risks and advantages. The stage and severity of the cancer, the mother's gestational age, and her health must be assessed to balance cancer control with fetal well-being. The multidisciplinary team's knowledge and the woman's values should inform treatment selections. Monitoring and follow-up throughout the pregnancy and beyond are essential to confirm therapy efficacy and address any issues.

References

Almonte, M., Murillo, R., Sánchez, G. I., González, P., Ferrera, A., Picconi, M. A., Wiesner, C., Cruz-Valdéz, A., Lazcano-Ponce, E., Jerónimo, J., Ferreccio, C., Kasamatsu, E., Mendoza, L., Rodríguez, G., Calderón, A., Venegas, G., Villagra, V., Tatti, S., Fleider, L., . . . Herrero, R. (2020). Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol. *BMJ Open, 10*(5), e035796. https://doi.org/10.1136/bmjopen-2019-035796

Canepa, M., Patel, N. R., & Garcia-Moliner, M. (2019). Pathology and molecular diagnosis of cervical cancer and precursor lesions. In *Springer eBooks* (pp. 61–87). https://doi.org/10.1007/978-3-030-02701-8_5

Dimova, I., Rizov, M., Giragosyan, S., Koprinarova, M., Tzoneva, Д., Belemezova, K., Hristova-Savova, M., Milachich, T., Djonov, V., & Shterev, A. (2020). Molecular pathogenesis of spontaneous abortions – Whole genome copy number analysis and expression of angiogenic factors. *Taiwanese Journal of Obstetrics & Gynecology, 59*(1), 99–104. https://doi.org/10.1016/j.tjog.2019.11.015

Esfandyari, S., Elkafas, H., Chugh, R. M., Park, H., Navarro, A., & Al-Hendy, A. (2021). Exosomes as Biomarkers for Female Reproductive Diseases diagnosis and therapy. *International Journal of Molecular Sciences, 22*(4), 2165. https://doi.org/10.3390/ijms22042165

Evans, I., Reisel, D., Jones, A., Bajrami, A., Nijjar, S., Solangon, S., Arora, R., Redl, E., Schreiberhuber, L., Ishaq-Parveen, I., Rothärmel, J., Herzog, C., Jurkovic, D., & Widschwendter, M. (2023). Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK. *Lancet Oncology.* https://doi.org/10.1016/s1470-2045(23)00466-7

Hamilton, C. A., Pothuri, B., Arend, R. C., Backes, F. J., Gehrig, P. A., Soliman, P. T., Thompson, J. S., Urban, R. R., & Burke, W. M. (2021). Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II. *Gynecologic Oncology,* 160(3), 827–834. https://doi.org/10.1016/j.ygyno.2020.12.024

Hampe, C. S., Eisengart, J. B., Lund, T. C., Orchard, P. J., Swietlicka, M., Wesley, J., & McIvor, R. S. (2020). Mucopolysaccharidosis type I: A review of the natural history and molecular pathology. *Cells, 9*(8), 1838. https://doi.org/10.3390/cells9081838

Hossain, M. S., Amin, M. A., Hasan, M. I., Sohel, M., Ahammed, M. A., Mahmud, S., Rahman, R., & Rahman, H. (2022). Bioinformatics and system biology approaches to identify molecular pathogenesis of polycystic ovarian syndrome, type 2 diabetes, obesity, and cardiovascular disease that are linked to the progression of female infertility. *Informatics in Medicine Unlocked, 30,* 100960. https://doi.org/10.1016/j.imu.2022.100960

Johnson, C., James, D., Marzan, A. B., & Armaos, M. (2019). Cervical Cancer: An Overview of Pathophysiology and management. *Seminars in Oncology Nursing, 35*(2), 166–174. https://doi.org/10.1016/j.soncn.2019.02.003

Martínez-Rodríguez, F., Limones-González, J. E., Mendoza-Almanza, B., Esparza-Ibarra, E., Gallegos-Flores, P., Ayala-Luján, J. L., Godina-González, S., Salinas, E., & Mendoza-Almanza, G. (2021). Understanding Cervical Cancer through Proteomics. *Cells, 10*(8), 1854. https://doi.org/10.3390/cells10081854

Nahand, J. S., Taghizadeh-Boroujeni, S., Karimzadeh, M. R., Borran, S., Pourhanifeh, M. H., Moghoofei, M., Bokharaei-Salim, F., Karampoor, S., Jafari, A. H., Asemi, Z., Tbibzadeh, A., Namdar, A., & Mirzaei, H. (2019). microRNAs: New prognostic, diagnostic, and therapeutic biomarkers in cervical cancer. *Journal of Cellular Physiology, 234*(10), 17064–17099. https://doi.org/10.1002/jcp.28457

Nayar, R., Chhieng, D. C., Crothers, B. A., Darragh, T. M., Davey, D. D., Eisenhut, C., Goulart, R. A., Huang, E. C., & Tabbara, S. O. (2020). Moving forward—the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories. *Journal of the American Society of Cytopathology, 9*(4), 291–303. https://doi.org/10.1016/j.jasc.2020.05.002

Olusola, P., Banerjee, H. N., Philley, J. V., & Dasgupta, S. (2019). Human Papilloma Virus-Associated cervical cancer and health disparities. *Cells, 8*(6), 622. https://doi.org/10.3390/cells8060622

Otto, C. (2023). Recently updated Sexually Transmitted Infection Screening Guidelines and Impact on Molecular Diagnostics. *Advances in Molecular Pathology, 6*(1), 69–75. https://doi.org/10.1016/j.yamp.2023.07.003

Pang, C., Lim, C. S., Brookes, J., Tsui, J., & Hamilton, G. (2020). Emerging importance of molecular pathogenesis of vascular malformations in clinical practice and classifications. *Vascular Medicine, 25*(4), 364–377. https://doi.org/10.1177/1358863x20918941

Perrone, A. M., Bovicelli, A., D'Andrilli, G., Borghese, G., Giordano, A., & De Iaco, P. (2019). Cervical cancer in pregnancy: Analysis of the literature and innovative approaches. *Journal of Cellular Physiology, 234*(9), 14975–14990. https://doi.org/10.1002/jcp.28340

Radaic, A., Ganther, S., Kamarajan, P., Grandis, J. R., Yom, S. S., & Kapila, Y. (2021). Paradigm shift in the pathogenesis and treatment of oral cancer and other cancers focused on the oralome and antimicrobial-based therapeutics. *Periodontology 2000, 87*(1), 76–93. https://doi.org/10.1111/prd.12388

Reed, N., Balega, J., Barwick, T., Buckley, L., Burton, K., Eminowicz, G., Forrest, J., Ganesan, R., Harrand, R., Holland, C., Howe, T., Ind, T., Iyer, R., Kaushik, S., Music, R., Sadozye, A., Shanbhag, S., Siddiqui, N., Syed, S., . . . Fotopoulou, C. (2021). British Gynaecological Cancer Society (BGCS) cervical

cancer guidelines: Recommendations for practice. *European Journal of Obstetrics & Gynecology and Reproductive Biology, 256,* 433–465. https://doi.org/10.1016/j.ejogrb.2020.08.020

Saiki, Y., Gion, Y., Nishikori, A., Norimatsu, Y., & Sato, Y. (2020). Comparison of the Hybrid Capture II Method with a PCR-Based Screening Method Using a Carboxyfluorescein-Labeled Primer for Detecting Human Papillomavirus in Cervicovaginal Liquid-Based Cytology. *Journal of Molecular Pathology, 1*(1), 9–18. https://doi.org/10.3390/jmp1010003

Zhang, W. (2019). *The exosome-mediated PI3k/Akt/mTOR signaling pathway in cervical cancer.* PubMed Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949546/